

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Dexcel Pharma Technologies Ltd.</u> _____ (Last) (First) (Middle) 1 DEXCEL STREET _____ (Street) OR AKIVA L3 3060000 _____ (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 01/01/2019	3. Issuer Name and Ticker or Trading Symbol <u>Intec Pharma Ltd. [NTEC]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	5,150,848	D ⁽¹⁾	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				

1. Name and Address of Reporting Person* <u>Dexcel Pharma Technologies Ltd.</u> _____ (Last) (First) (Middle) 1 DEXCEL STREET _____ (Street) OR AKIVA L3 3060000 _____ (City) (State) (Zip)
--

1. Name and Address of Reporting Person* <u>Oren Dan</u> _____ (Last) (First) (Middle) 1 DEXCEL STREET _____ (Street) OR AKIVA L3 3060000 _____ (City) (State) (Zip)

Explanation of Responses:

1. Dexcel Pharma Technologies Ltd. ("DPT") and DPT's President and Chief Executive Officer, Dan Oren, are filing this Form 3 because they may be deemed to have beneficial ownership over 5,150,848 ordinary shares (the "Common Shares") of Intec Pharma Ltd. (the "Issuer"). The Common Shares are directly owned by DPT. Mr. Oren is ultimately the sole shareholder of DPT.

/s/ Dexcel Pharma
Technologies Ltd. by Dan 02/14/2019
Oren, President and CEO

/s/ Dan Oren 02/14/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.